Study of Alectinib as Additional Treatment After Surgery for Adults with ALK-Positive Stage II-IIIB Non-Small-Cell Lung Cancer in China

What this Trial Is About

Researchers are evaluating the clinical outcomes and characteristics of adult patients in China with resected stage II to IIIB anaplastic lymphoma kinase ALK-positive non-small-cell lung cancer NSCLC who have been treated with Alectinib as adjuvant therapy. This multicenter, prospective cohort study aims to observe these patients in real-world clinical practice settings to better understand their disease progression and response to treatment. Participants in this observational study have already received Alectinib monotherapy as adjuvant therapy following complete surgical resection of their NSCLC. No additional intervention is provided by the study. Patients are followed for approximately 2.5 years during routine clinical visits to monitor their health status and treatment outcomes. During the study, participants will have periodic assessments including evaluations of disease-free survival, treatment duration, clinical characteristics, and quality of life using the 36-item short form survey SF-36 every three months. Researchers will also monitor adverse events from the time of enrollment until 28 days after the last dose of Alectinib or withdrawal from the study. The total follow-up period is up to approximately 2.5 years.

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy